The influence of EIF4A1 overexpression on patient OS was evaluated using the publicly available dataset of the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative (clinicopathological data of 141 NB patients with an available MYCN status were included; see Supplementary Table S1). This evidence concerns the gene EIF4A1 and neuroblastoma.